



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

ADT-007

Cat. No.:	HY-157887		
CAS No.:	1945941-09-2		
Molecular Formula:	C ₂₆ H ₂₄ FNO ₅		
Molecular Weight:	449.47		
Target:	Ras		
Pathway:	GPCR/G Protein; MAPK/ERK Pathway		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (278.11 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.2248 mL	11.1242 mL	22.2484 mL
		5 mM	0.4450 mL	2.2248 mL	4.4497 mL
10 mM		0.2225 mL	1.1124 mL	2.2248 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 6.25 mg/mL (13.91 mM); Clear solution; Need ultrasonic and warming and heat to 60°C				

BIOLOGICAL ACTIVITY

Description	ADT-007 is a potent and orally active pan-RAS inhibitor with strong anticancer effects. ADT-007 binds RAS in a nucleotide-free conformation to block GTP activation. ADT-007 potently and selectively inhibits the growth of cancer cells with mutated or hyper-activated wild-type RAS isozymes ^[1] .
In Vitro	ADT-007 displays the highest potency and selectivity to inhibit the growth of KRASG13D HCT-116 cells with an IC ₅₀ of 5 nM, while RAS 110 wild-type HT-29 cells are ~100 fold less sensitive with an IC ₅₀ of 493 nM. ADT-007 displays even greater potency in KRAS G12C MIA PaCa-2 PDA cells, resulting in IC ₅₀ values as low as 2 nM. ADT-007 also potently inhibits the growth of three other mutant KRAS PDA cell lines with G12V or G12D mutations ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	ADT-007 (10 mg/kg; intra-tumoral injection; once a day; for 17-21 days) strongly inhibits tumor growth in syngeneic immune competent mouse models of colorectal cancer ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-8-week-old BALB/C mice injected with colorectal cancer cells ^[1]
Dosage:	10 mg/kg
Administration:	intra-tumoral injection; once a day; for 17-21 days
Result:	Strongly inhibited tumor growth.

REFERENCES

[1]. Jeremy B Foote, et al. A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer. bioRxiv[Preprint]. 2024 Jan 24:2023.05.17.541233.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA